Allgenesis reports promising initial safety and effectiveness results for AG-73305 phase 2a trial tackling Diabetic Macular Edema, presented at the American Academy of Ophthalmology.

This article summarized the latest R&D progress of TBO-Filgrastim, the Mechanism of Action for TBO-Filgrastim, and the drug target R&D trends for TBO-Filgrastim.

Takeda has announced FDA approval for its oral drug, FRUZAQLA™ (fruquintinib), designed to treat adults with metastatic colorectal cancer who have previously received chemotherapy, anti-VEGF, and applicable anti-EGFR therapies.

Several selective CDK7 inhibitors, which have entered clinical trials, have demonstrated effective anti-cancer results in numerous pre-clinical models.

The EU has sanctioned VANFLYTA®, the initial FLT3 inhibitor tailored for recently identified patients with FLT3-ITD positive AML.

The ESMO Congress presented a summary of the RATIONALE-315 phase III trial: Neoadjuvant tislelizumab plus platinum-based chemotherapy showed a pathological response in operable stage II-IIIA NSCLC, prompting detailed trial result discussions.

This article summarized the latest R&D progress of Tirbanibulin, the Mechanism of Action for Tirbanibulin, and the drug target R&D trends for Tirbanibulin.

CETP inhibitors are drugs designed to increase HDL-C levels which can improve cardiovascular health.

Orum Therapeutics has announced a final agreement with Bristol Myers Squibb for the acquisition of its ORM-6151 program.

On 23 Oct 2023, liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib was reported at the ESMO Congress.

This article summarized the latest R&D progress of Tolcapone, the Mechanism of Action for Tolcapone, and the drug target R&D trends for Tolcapone.

In biology, a neoantigen refers to a novel antigen that arises from a mutation in the DNA of a normal cell.